PRELUDE THERAPEUTICS INC Accounts Payable
PRELUDE THERAPEUTICS INC (PRLD) had Accounts Payable of $2.03 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-11
- 2026-06-30: Accounts Payable, Current $2.03M.
- 2026-03-31: Accounts Payable, Current $2.07M.
- 2025-12-31: Accounts Payable, Current $3.98M.
- 2025-09-30: Accounts Payable, Current $2.53M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $2.03M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $2.07M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $3.98M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $2.53M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $4.96M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $5.83M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $7.73M 10-K · filed 2026-03-10 |
| 2024-09-30 | $5.92M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $6.17M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $5.31M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $4.58M 10-K · filed 2025-03-10 |
| 2023-09-30 | $5.17M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $5.58M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $7.08M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $6.78M 10-K · filed 2024-02-15 |
| 2022-09-30 | $10.25M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $6.27M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $7.39M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $7.84M 10-K · filed 2023-03-15 |
| 2021-09-30 | $11.06M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $6.84M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $4.84M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $3.92M 10-K · filed 2022-03-17 |
| 2020-09-30 | $5.07M 10-Q · filed 2020-11-10 |
| 2019-12-31 | $1.97M 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |